Leerink Partnrs Has Pessimistic Outlook of Merus Q2 Earnings

Merus (NASDAQ:MRUS) – Equities researchers at Leerink Partnrs reduced their Q2 2025 earnings estimates for shares of Merus in a research report issued on Wednesday, May 7th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings of ($1.29) per share for the quarter, down from their previous estimate of ($1.27). The consensus estimate for Merus’ current full-year earnings is ($3.85) per share. Leerink Partnrs also issued estimates for Merus’ Q3 2025 earnings at ($1.32) EPS, Q4 2025 earnings at ($1.33) EPS, FY2025 earnings at ($5.33) EPS, FY2026 earnings at ($2.72) EPS and FY2027 earnings at $4.01 EPS.

Several other research analysts have also recently weighed in on MRUS. Wells Fargo & Company dropped their price objective on shares of Merus from $91.00 to $89.00 and set an “overweight” rating for the company in a research report on Thursday. HC Wainwright restated a “buy” rating and issued a $85.00 price objective on shares of Merus in a research report on Monday, March 3rd. Guggenheim restated a “buy” rating and issued a $109.00 price objective on shares of Merus in a research report on Friday, March 28th. Needham & Company LLC restated a “buy” rating and issued a $83.00 price objective on shares of Merus in a research report on Wednesday, April 9th. Finally, Piper Sandler assumed coverage on shares of Merus in a research report on Thursday, February 13th. They issued an “overweight” rating and a $84.00 price objective for the company. One research analyst has rated the stock with a sell rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $85.15.

Merus Trading Down 3.4%

NASDAQ:MRUS opened at $41.32 on Monday. Merus has a 1 year low of $33.19 and a 1 year high of $61.61. The firm has a 50 day moving average of $43.51 and a 200-day moving average of $44.04. The stock has a market capitalization of $2.86 billion, a P/E ratio of -10.46 and a beta of 0.94.

Merus (NASDAQ:MRUS) last posted its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.23). Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The company had revenue of $26.49 million for the quarter, compared to the consensus estimate of $7.82 million.

Institutional Investors Weigh In On Merus

Several institutional investors have recently added to or reduced their stakes in MRUS. KBC Group NV lifted its holdings in Merus by 4,583.6% in the fourth quarter. KBC Group NV now owns 57,234 shares of the biotechnology company’s stock worth $2,407,000 after buying an additional 56,012 shares during the period. State of New Jersey Common Pension Fund D lifted its holdings in Merus by 29.0% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 48,268 shares of the biotechnology company’s stock worth $2,030,000 after buying an additional 10,842 shares during the period. Raymond James Financial Inc. purchased a new stake in Merus in the fourth quarter worth about $347,000. Swiss National Bank lifted its holdings in Merus by 9.7% in the fourth quarter. Swiss National Bank now owns 93,954 shares of the biotechnology company’s stock worth $3,951,000 after buying an additional 8,300 shares during the period. Finally, Baker BROS. Advisors LP lifted its holdings in Merus by 50.0% in the fourth quarter. Baker BROS. Advisors LP now owns 450,000 shares of the biotechnology company’s stock worth $18,922,000 after buying an additional 150,000 shares during the period. Hedge funds and other institutional investors own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.